Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year High at $26.61
Shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) reached a new 52-week high during trading on Tuesday . The company traded as high as $26.61 and last traded at $26.61, with a volume of 8641 shares. The stock had previously closed at $25.92.
APLS has been the topic of a number of research analyst reports. ValuEngine raised shares of Vistra Energy from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. Cowen reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Sunday, June 16th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $107.00 price target on shares of Perrigo in a report on Wednesday, May 8th. Zacks Investment Research raised shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a report on Friday, May 17th. Finally, Robert W. Baird started coverage on shares of Uniqure in a report on Thursday, March 28th. They issued an “outperform” rating and a $85.00 price target on the stock. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $43.29.
The firm has a market capitalization of $1.61 billion, a P/E ratio of -11.16 and a beta of 0.74. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $22.72.
Several institutional investors and hedge funds have recently made changes to their positions in APLS. Flinton Capital Management LLC purchased a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at approximately $36,000. SG Americas Securities LLC purchased a new position in shares of Apellis Pharmaceuticals during the first quarter valued at approximately $112,000. PNC Financial Services Group Inc. lifted its stake in shares of Apellis Pharmaceuticals by 35.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,380 shares of the company’s stock valued at $124,000 after buying an additional 2,440 shares during the period. BNP Paribas Arbitrage SA lifted its stake in shares of Apellis Pharmaceuticals by 250,533.3% during the first quarter. BNP Paribas Arbitrage SA now owns 7,519 shares of the company’s stock valued at $147,000 after buying an additional 7,516 shares during the period. Finally, Metropolitan Life Insurance Co. NY lifted its stake in shares of Apellis Pharmaceuticals by 356.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,216 shares of the company’s stock valued at $161,000 after buying an additional 9,541 shares during the period. 63.45% of the stock is currently owned by institutional investors and hedge funds.
About Apellis Pharmaceuticals (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Further Reading: Stop Order Uses For Individual Investors
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.